Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of$ 0.92. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.87%. A quarter ago, it was expected that this company would post a loss of$ 0.76 per share when it actually produced a loss of $0.88, delivering a surprise of -15.79%.Over the last four quarters, the company h ...